Cancer Genomics is a relatively new research area that takes advantage of recent technological advances to study the human genome, meaning our full set of DNA. Genomics is transforming how we study, diagnose and treat cancer.
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
DATE: February 26, 2019TIME: 9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
DATE: December 11, 2018TIME: 06:00 PSTIt’s understood and accepted that animal disease models generally offer great value for pre-clinical research and efficient drug screeni...
DATE: November 28, 2018TIME: 7:00AM PSTSingle-cell genomics enables a deep dive into the mechanisms responsible for health and disease, in areas from cancer biology to neurob...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAG...
Clinical testing with next generation sequencing requires a complex bioinformatics pipeline to process raw DNA sequence into interpretable variants for medical reporting. With sequencin...
The use of human pluripotent stem cells (hPSCs) for in vitro disease-modeling is limited by the lack of robust and efficient protocols for the differentiation of relevant adult cell types. Pr...
As the compendium of putatively disease causing variants expands, gathering the most current and accurate information is critical to computing variant classifications. The QIAGEN knowledgebas...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
DATE: October 30, 2018TIME: 9:00AM PSTMass spectrometry-based proteomics is a rapidly growing area of research that provides useful information for many fields including basi...
DATE: October 23, 2018TIME: 10:00am PDT, 1:00pm EDT Next-generation genomic sequencing is transforming what is known about pediatric cancer and how we treat patients. But eve...
DATE: October 23, 2018TIME: 9:00AM PDTIxodes scapularis is the principal vector of the Lyme disease spirochete, Borrelia burgdorferi. I. scapularis genome was the first and only...
Recent work has identified epigenomic features of distal regulatory elements to be dynamic and defining indicators of cellular specification and transformation. Of particular relevance is our...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
In the last two decades, large amount of next-generation sequencing (NGS) and -omics data has been generated in the field of immuno-oncology. Generating hypotheses by analyzing hundreds if no...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expres...
PacBio Sequencing simultaneously provides long sequence reads, high consensus accuracy, minimal sequence bias, and methylation detection. I will highlight new advances and updates on applying...
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
DATE: February 26, 2019TIME: 9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
DATE: December 11, 2018TIME: 06:00 PSTIt’s understood and accepted that animal disease models generally offer great value for pre-clinical research and efficient drug screeni...
DATE: November 28, 2018TIME: 7:00AM PSTSingle-cell genomics enables a deep dive into the mechanisms responsible for health and disease, in areas from cancer biology to neurob...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAG...
Clinical testing with next generation sequencing requires a complex bioinformatics pipeline to process raw DNA sequence into interpretable variants for medical reporting. With sequencin...
The use of human pluripotent stem cells (hPSCs) for in vitro disease-modeling is limited by the lack of robust and efficient protocols for the differentiation of relevant adult cell types. Pr...
As the compendium of putatively disease causing variants expands, gathering the most current and accurate information is critical to computing variant classifications. The QIAGEN knowledgebas...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
DATE: October 30, 2018TIME: 9:00AM PSTMass spectrometry-based proteomics is a rapidly growing area of research that provides useful information for many fields including basi...
DATE: October 23, 2018TIME: 10:00am PDT, 1:00pm EDT Next-generation genomic sequencing is transforming what is known about pediatric cancer and how we treat patients. But eve...
DATE: October 23, 2018TIME: 9:00AM PDTIxodes scapularis is the principal vector of the Lyme disease spirochete, Borrelia burgdorferi. I. scapularis genome was the first and only...
Recent work has identified epigenomic features of distal regulatory elements to be dynamic and defining indicators of cellular specification and transformation. Of particular relevance is our...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
In the last two decades, large amount of next-generation sequencing (NGS) and -omics data has been generated in the field of immuno-oncology. Generating hypotheses by analyzing hundreds if no...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expres...
PacBio Sequencing simultaneously provides long sequence reads, high consensus accuracy, minimal sequence bias, and methylation detection. I will highlight new advances and updates on applying...
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...